Pharmascience Canada launched (PR)pms-DEFERASIROX (TYPE J), a generic drug indicated in the management of chronic iron
MONTRÉAL, Jan. 18, 2023 /CNW Telbec/ - Pharmascience Canada now adds PRpms-DEFERASIROX (TYPE J) to its product catalogue, available in 90 mg and 360 mg tablets. The 180 mg tablets will be available in a few weeks only.
pms-DEFERASIROX (TYPE J) is used to treat chronic iron overload in:
With the same safety and efficacy profile as the brand-name product, Jadenu®, PRpms-DEFERASIROX (TYPE J) is available at a lower cost.
ABOUT PHARMASCIENCE INC.
Founded in 1983, Pharmascience Inc. is the largest pharmaceutical employer in Quebec with 1,500 employees proudly headquartered in Montreal. Pharmascience Inc. is a full-service privately owned pharmaceutical company with strong roots in Canada and a growing global reach with product distribution in over 50 countries. Ranked 47th among Canada's top 100 Research & Development (R&D) investors in 2020, with 40-50 million dollars invested each year, Pharmascience Inc. is among the largest drug manufacturers in Canada.
Pharmascience Inc. has strong values based on the importance of investing in its employees and young people. Through various programs and initiatives, the company ensures it supports their personal development and life. In 2022, Pharmascience Inc. has proudly been recognized for its investments by being selected as one of Canada's Top Employers for Young People and named as one of Montreal's best employers, as part of the Canada's Top 100 Employers project. Pharmascience is now certified as a Great Place to Work.
For product information, please contact Pharmascience's Medical Information Department at 1-888-550-6060.
Jadenu® is a registered trademark of Novartis AG.
SOURCE Pharmascience Inc.